Vol.58 No.2 March 2010
Therapeutic drug monitoring survey of anti-MRSA agents in Japan
Working group for therapeutic drug monitoring standardization of antibiotics, Infectious Disease Chemotherapy Pharmacist Committee, the Japanese Society of Chemotherapy, Nichinai Kaikan B1, 3-28-8 Hongo, Bunkyo-ku, Tokyo, Japan
Abstract
We distributed questionnaires to determine therapeutic drug monitoring(TDM) status for anti-MRSA agents vancomycin(VCM), teicoplanin(TEIC), and arbekacin(ABK) in 563 Japanese hospitals having pharmacists enrolled in the Japanese Society of Chemotherapy. Responses were collected from 302 (53.6%) institutions. In over 80% of facilities, pharmacists provide clinical consultation on anti-MRSA agents based on TDM. General recommendations for monitoring serum drugs concentrations are as follows: (1) VCM, trough concentration on day 3 targeting >10 μg/mL; (2) TEIC, on day 4 targeting >15 μg/mL; and (3) ABK, on day 3 targeting <2 μg/mL and peak >9 μg/mL. Answers for main questions such as sample timing, sampling points, and targeted concentrations, were roughly equivalent to our recommendations. Standardizing TDM involves problems including large inter institutional differences in ABK TDM and no claim of rights to cost monitoring more than twice a month under the current government-run health insurance system.
Key word
therapeutic drug monitoring, vancomycin, teicoplanin, arbekacin, questionnaire
Received
January 20, 2010
Accepted
February 4, 2010
Jpn. J. Chemother. 58 (2): 119-124, 2010
